Please assess the completion status of the following clinical trial:

Trial Title: Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Signed written informed consent~* Histologically or cytological diagnosed stage IIIB/IV non-squamous histology NSCLC~* Received platinum based doublet chemotherapy for 4 cycles as first line therapy before this study~* Patients upon enrolment has at least stable disease following the platinum doublet; with documented (confirmed or unconfirmed) radiographic evidence of a tumor response of complete response (CR), partial response (PR), or stable disease (SD) according to RECIST version 1.1 criteria~* Estimated Life expectancy ≥ 3 months~* Eastern cooperative oncology group performance status (ECOG PS) 0-2~* Adequate organ function~Exclusion Criteria:~* Age ˂18 years~* Predominantly squamous cell and/or mixed small cell, non-small cell histology~* Current treatment on another therapeutic clinical study or within the last 30 days of entering the study~* Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function, carcinomatous meningitis, or leptomeningeal disease~* Any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack~* Ongoing cardiac dysrhythmias of national cancer institute-common terminology criteria for adverse events (NCI CTCAE) Grade \>2, uncontrolled atrial fibrillation of any grade, or corrected QT interval (QTc) \>470 msec~* Pregnancy or breastfeeding~* Prior malignancy (other than current NSCLC): patients will not be eligible if they have evidence of active malignancy (other than non-melanoma skin cancer or localized cervical cancer, or localized and presumed cured prostate cancer) within the last 3 years~* Other severe acute or chronic medical or psychiatric conditions, or laboratory abnormalities that would impose, in the judgment of the investigator and/or sponsor, excessive risk associated with study participation or study drug administration, and which would, therefore, make the patient inappropriate to enter this study~* Uncontrolled third-space fluid collections~* Progressive brain metastases~* Hypersensitivity to the study drugs~* Inability to take corticosteroid drugs, folic acid, or vitamin B12~* Patients with epidermal growth factor receptor (EGFR) positive, anaplastic lymphoma kinase (ALK) positive (documented using fluorescence in situ hybridization (FISH) and/or immunohistochemistry (IHC)), or unknown EGFR and ALK test results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed Arm (Type: OTHER): Vials containing powder for concentrate for solution for infusion equivalent to 500 mg of pemetrexed (as disodium)
- Erlotinib Arm (Type: OTHER): Film coated tablets containing 150 mg erlotinib (as erlotinib hydrochloride)

Based on this trial design, predict the completion outcome and termination type (if applicable).